Page 1510 - Williams Hematology ( PDFDrive )

1484 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1485

700. Ullmann AJ, Hess G, Kolbe K, et al: Current results on the use of imatinib mesylate in 730. Usman M, Syed NN, Kakepoto GN, et al: Chronic phase chronic myeloid leukemia:
patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or Response of imatinib mesylate and significance of Sokal score, age and disease dura-
syngeneic hematopoietic stem cell transplantation. Keio J Med 52:182, 2003. tion in predicting the hematological and cytogenetic response. J Assoc Physicians
701. Olavarria E, Craddock C, Dazzi F, et al: Imatinib mesylate (STI571) in the treatment of India 55:103, 2007.
relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 731. Rosti G, Martinelli G, Bassi S, et al: Molecular response to imatinib in late chronic-
99:3861, 2002. phase chronic myeloid leukemia. Blood 103:2284, 2004.
702. Weisser M, Tischer J, Schnittger S, et al: A comparison of donor lymphocyte infu- 732. Lauseker M, Hasford J, Pfirmann M, et al: The impact of health care settings on sur-
sions or imatinib mesylate for patients with chronic myelogenous leukemia who have vival time of patients with chronic phase myeloid leukemia. Blood 123:2494, 2014.
relapsed after allogeneic stem cell transplantation. Haematologica 91:663, 2006 733. Boehm A, Walcherberger B, Sperr WR, et al: Improved outcome in patients with
703. Savani BN, Montero A, Kurlander R, et al: Imatinib synergizes with donor lymphocyte chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem over the past 25 years: A single center experience. Biol Blood Marrow Transplant
stem cell transplantation. Bone Marrow Transplant 36;1009, 2005. 17:133, 2011.
704. Bar M, Radich J: Maintenance therapy with tyrosine kinase inhibitors after transplant 734. Goldman JM, Majhail NS, Klein JP, et al: Relapse and late mortality in 5-year survivors
in patients with chronic myeloid leukemia. J Natl Compr Canc Netw 11:308, 2013. of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid
705. Carpenter PA, Snyder DS, Flowers ME, et al: Prophylactic administration of imatinib leukemia in first chronic phase. J Clin Oncol 28:1888, 2010.
after hematopoietic cell transplantation for high-risk Philadelphia chromosome- 735. Khoury HJ, Kukreja M, Goldman JM, et al: Prognostic factors for outcomes in allo-
positive leukemia. Blood 109:2791, 2007. geneic transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era:
706. Olavarria E, Siddique S, Griffiths MJ, et al: Posttransplantation imatinib as a strategy Evaluation of its impact within a subgroup of the randomized German CMLA Study
to postpone the requirement for immunotherapy in patients undergoing reduced- IV. Blood 115:1880, 2010.
intensity allografts for chronic myeloid leukemia. Blood 110:4614, 2007. 736. Yee K, Anglin P, Keating A: Molecular approaches to the detection and monitoring of
707. Sullivan KM: Marrow transplantation for disorders of hematopoiesis. Leukemia chronic myeloid leukemia: Theory and practice. Blood Rev 13:105, 1999.
7:1098, 1993. 737. Hughes T, Branford S: Molecular monitoring of chronic myeloid leukemia. Semin
708. Kolb HJ, Mittermuller J, Clemm CH, et al: Donor leukocyte transfusions for treatment Hematol 40:62, 2003.
of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 738. Kantarjian H, Schiffer C, Jones D, Cortes J: Monitoring the response and course of
2462, 1990. chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhib-
709. Dazzi F, Szydlo RM, Goldman JM: Donor lymphocyte infusion for relapse of chronic itors: Practical advice on the use and interpretation of monitoring methods. Blood
myeloid leukemia after allogeneic stem cell transplant: Where we now stand. Exp 111(4):1774, 2008.
Hematol 27:1477, 1999. 739. Lowenberg B: Minimal residual disease in chronic myeloid leukemia. N Engl J Med
710. Van Rhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia after allogeneic 349:1399, 2003.
bone marrow transplant: The case of giving donor leukocyte transfusions before the 740. Gabert J: Detection of recurrent translocations using real time PCR; assessment of
onset of hematologic relapse. Blood 83:3377, 1994. the technique for diagnosis and detection of minimal residual disease. Haematologica
711. Leis J, Porter DL: Unrelated donor leukocyte infusions to treat relapse after unrelated 84:107, 1999.
donor bone marrow transplantation. Leuk Lymphoma 43:9, 2002. 741. Negrin RS, Blume KG: The use of polymerase chain reaction for the detection of min-
712. Dazzi F, Goldman J: Donor lymphocyte infusions. Curr Opin Hematol 6:394, 1999. imal residual malignant disease. Blood 78:255, 1991.
713. Dazzi F, Szydlo RM, Cross NCP, et al: Durability of responses following donor lym- 742. Lee MS, Kantarjian H, Talpaz M, et al: Detection of minimal residual disease by poly-
phocyte infusions for patients who relapse after allogeneic stem cell transplantation merase chain reaction in Philadelphia chromosome-positive chronic myelogenous
for chronic myeloid leukemia. Blood 96:2712, 2000. leukemia following interferon therapy. Blood 79:1920, 1992.
714. Dazzi F: Monitoring of minimal residual disease after allografting: A requirement to 743. Branford S, Fletcher L, Cross NC, et al: Desirable performance characteristics for
guide DLI treatment. Ann Hematol 81 Suppl 2:S29, 2002. BCR-ABL measurement on an international reporting scale to allow consistent inter-
715. Porter D, Levine JE: Graft-versus-host disease and graft-versus-leukemia after donor pretation of individual patient response and comparison of response rates between
leukocyte infusion. Semin Hematol 43:53, 2006. clinical trials. Blood 112:3330, 2008.
716. MacKinnon S: Donor leukocyte infusions. Baillieres Clin Haematol 10:357, 1997. 744. Sahay T, Schiffer CA: Monitoring minimal residual disease in patients with chronic
717. Giralt S, Hester J, Huh T, et al: CD8-depleted donor lymphocyte infusion as treatment myeloid leukemia after treatment with tyrosine kinase inhibitors. Curr Opin Hematol
for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplan- 15:134, 2008.
tation. Blood 86:4337, 1995. 745. Stock W, Yu D, Karrison T, et al: Quantitative real-time RT-PCR monitoring of BCR-
718. Guglielma C, Arcese W, Dazzi F, et al: Donor lymphocyte infusion for relapsed ABL in chronic Myelogenous leukemia shows lack of agreement in blood and bone
chronic myelogenous leukemia: Prognostic relevance of the initial cell dose. Blood marrow samples. Int J Oncol 28:1099, 2006
100:397, 2002. 746. Hughes T, Deininger M, Hochhaus A, et al: CML patients responding to treatment
719. Savani BN, Montero A, Kurlander R, et al: Imatinib synergizes with donor lymphocyte with tyrosine kinase inhibitors: Review and recommendations for harmonizing cur-
infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem rent methodology for detecting BCR-ABL transcripts and kinase domain mutations
cell transplantation. Bone Marrow Transplant 36:1009, 2005. and for expressing results. Blood 108:28, 2006.
720. Huang X, Cortes J, Kantarjian H: Estimations of the increasing prevalence and plateau 747. Iacobucci I, Saglio G, Rosti G, et al: Achieving a major molecular response at the
prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR
Cancer 118:3123, 2012. in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12:3037,
721. Bjorkholm M, Ohm L, Eloranta S, et al: Success of targeted therapy in chronic myeloid 2006.
leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 748. Press RD, Love Z, Tronnes AA, et al: BCR-ABL mRNA levels at and after the time
2008. J Clin Oncol 29:2514, 2011. of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib
722. Höglund M, Sandin F, Hellström K, et al: Tyrosine kinase inhibitor usage, treatment, mesylate-treated patients with CML. Blood 107:4250, 2006.
outcome, and prognostic scores in CML: Report from the population-based Swedish 749. Jabbour E, Cortes JE, Kantarjian HM: Molecular monitoring in chronic myeloid leu-
CML registry. Blood 122:1284, 2013. kemia: Response to tyrosine kinase inhibitors and prognostic implications. Cancer
723. Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients receiving ima- 112:2112, 2008.
tinib for chronic myeloid leukemia. N Engl J Med 355:2408, 2006. 750. Jain P, Kantarjian H, Nazha A, et al: Early responses predict better outcomes in
724. Rosti G, Iacobucci I, Bassi S, et al: Impact of age on the outcome of patients with patients with newly diagnosed chronic myeloid leukemia; results with four tyrosine
chronic myeloid leukemia in late chronic phase: Results of a phase II study of the kinase inhibitor modalities. Blood 121:4867, 2013.
GIMEMA CML Working Party. Haematologica 92:101, 2007. 751. Cohen N, Novikov I, Hardan I, et al: Standardization criteria for the detection of BCR/
725. Kantarjian H, O’Brien S, Talpaz M, et al: Outcome of patients with Philadelphia ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluores-
chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. cence in situ hybridization. Cancer Genet Cytogenet 123:102, 2000.
Cancer 109:1556, 2007. 752. Rheinhold U, Hennig E, Leiblein S, et al: FISH for BCR-ABL on interphases of periph-
726. Kantarjian H, O’Brien S, Jabbour E, et al: Improved survival in chronic myeloid eral blood neutrophils but not of unselected white cells correlates with bone marrow
leukemia since the introduction of imatinib therapy: A single-institution historical cytogenetics in CML patients treated with imatinib. Leukemia 17:1925, 2003.
experience. Blood 119:1981, 2012. 753. Kim YJ, Kim DW, Lee S, et al: Comprehensive comparison of FISH, RT-PCR, and
727. Passweg JR, Walker I, Sobocinski KA, et al: Validation and extension of the EBMT RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplan-
Risk Score for patients with chronic myeloid leukemia (CML) receiving allogeneic tation in CML. Eur J Haematol 68:272, 2002.
haematopoietic stem cell transplants. Br J Haematol 125:613, 2004. 754. Bao F, Munker R, Lowery C, et al: Comparison of FISH and quantitative RT-PCR for the
728. Hasford J, Pfirrmann M, Hehlmann R, et al: Prognosis and prognostic factors for diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther 11:239, 2007.
patients with chronic myeloid leukemia: Nontransplant therapy. Semin Hematol 40:4, 755. Uzunel M, Mattsson J, Brune M, et al: Kinetics of minimal residual disease and chime-
2003. rism in patients with chronic myeloid leukemia after nonmyeloablative conditioning
729. Qazilbash MH, Devetten MP, Abraham J, et al: Utility of a prognostic scoring system and allogeneic stem cell transplantation. Blood 101:469, 2003.
for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. 756. Hochhaus A, Weisser A, LaRosee P, et al: Detection and quantification of residual
Acta Haematol 109:119, 2003. disease in chronic myelogenous leukemia. Leukemia 14:998, 2000.

Kaushansky_chapter 89_p1437-1490.indd 1485 9/18/15 3:42 PM